1.Recent advances in the study of new antifungal lead compounds.
Sheng-zheng WANG ; Chun-quan SHENG ; Wan-nian ZHANG
Acta Pharmaceutica Sinica 2010;45(8):966-975
In recent years, the incidence and mortality rate of invasive fungal infection have increased dramatically, and it is of great significance to develop novel antifungal agents with new chemical structure and new mode of action. In this review, novel antifungal lead compounds reported from 2007 to 2009 are reviewed. Moreover, their chemical structures, antifungal activities and structure-activity relationships have been summarized, which can provide useful information for future study of antifungal agents.
Antifungal Agents
;
chemical synthesis
;
chemistry
;
pharmacology
;
therapeutic use
;
Fungi
;
drug effects
;
Heterocyclic Compounds
;
chemical synthesis
;
chemistry
;
pharmacology
;
Humans
;
Lipopeptides
;
chemistry
;
pharmacology
;
therapeutic use
;
Molecular Structure
;
Mycoses
;
drug therapy
;
Nitriles
;
chemistry
;
pharmacology
;
therapeutic use
;
Plant Extracts
;
chemical synthesis
;
chemistry
;
isolation & purification
;
pharmacology
;
Plants, Medicinal
;
chemistry
;
Pyridines
;
chemistry
;
pharmacology
;
therapeutic use
;
Quinazolines
;
chemistry
;
pharmacology
;
therapeutic use
;
Quinones
;
chemical synthesis
;
chemistry
;
pharmacology
;
Structure-Activity Relationship
;
Thiazoles
;
chemistry
;
pharmacology
;
therapeutic use
;
Triazoles
;
chemistry
;
pharmacology
;
therapeutic use
2.Advances in research on treatment of breast cancer with lapatinib.
Chuan-Dong MA ; Kun-Wei SHEN ; Zhen-Zhou SHEN
Chinese Journal of Oncology 2008;30(5):321-324
Animals
;
Antineoplastic Agents
;
pharmacology
;
therapeutic use
;
Brain Neoplasms
;
drug therapy
;
secondary
;
Breast Neoplasms
;
drug therapy
;
metabolism
;
pathology
;
Cell Proliferation
;
drug effects
;
Humans
;
Quinazolines
;
pharmacology
;
therapeutic use
;
Receptor, Epidermal Growth Factor
;
metabolism
;
Receptor, ErbB-2
;
metabolism
3.miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer.
Fa-Yong HU ; Xiao-Nian CAO ; Qin-Zi XU ; Yu DENG ; Sen-Yan LAI ; Jing MA ; Jun-Bo HU
Journal of Huazhong University of Science and Technology (Medical Sciences) 2016;36(6):839-845
Gefitinib is used as a first-line treatment for advanced non-small cell lung cancer (NSCLC). Unfortunately, most NSCLC patients inevitably develop gefitinib resistance during treatment. In addition to EGFR mutation status, the mechanisms involved are largely unknown. In this study, we showed that miR-124, a tumor suppressor, was significantly down-regulated in gefitinib-resistant NSCLC patients and cell lines compared with gefitinib-sensitive patients and cell lines. In addition, the miR-124 depletion induced gefitinib resistance, and miR-124 overexpression sensitized gefitinib-resistant cells to gefitinib. Mechanistic analysis revealed that miR-124 decreased SNAI2 and STAT3 expression by directly targeting their 3'UTRs and that knocking down SNAI2 or STAT3 partly reversed the gefitinib resistance induced by miR-124 depletion. Our data demonstrate that the miR-124 plays a new critical role in acquired resistance to gefitinib and that the manipulation of miR-124 might provide a therapeutic strategy for reversing acquired gefitinib resistance.
3' Untranslated Regions
;
Antineoplastic Agents
;
pharmacology
;
therapeutic use
;
Carcinoma, Non-Small-Cell Lung
;
drug therapy
;
genetics
;
metabolism
;
Cell Line, Tumor
;
Drug Resistance, Neoplasm
;
genetics
;
HEK293 Cells
;
Humans
;
Lung Neoplasms
;
drug therapy
;
genetics
;
metabolism
;
MicroRNAs
;
genetics
;
Quinazolines
;
pharmacology
;
therapeutic use
;
STAT3 Transcription Factor
;
genetics
;
metabolism
;
Snail Family Transcription Factors
;
genetics
;
metabolism
4.Rutaecarpine Inhibits Intimal Hyperplasia in A Balloon-Injured Rat Artery Model.
Yang XU ; Xiu-Ping CHEN ; Feng ZHANG ; Hua-Hua HOU ; Jing-Yi ZHANG ; Shu-Xian LIN ; An-Sheng SUN
Chinese journal of integrative medicine 2018;24(6):429-435
OBJECTIVETo investigate the effect and potential mechanisms of rutaecarpine (Rut) in a rat artery balloon-injury model.
METHODSThe intimal hyperplasia model was established by rubbing the endothelia with a balloon catheter in the common carotid artery (CCA) of rats. Fifty rats were randomly divided into five groups, ie. sham, model, Rut (25, 50 and 75 mg/kg) with 10 rats of each group. The rats were treated with or without Rut (25, 50, 75 mg/kg) by intragastric administration for 14 consecutive days following injury. The morphological changes of the intima were evaluated by hematoxylin-eosin staining. The expressions of proliferating cell nuclear antigen (PCNA) and smooth muscle (SM) α-actin in the ateries were assayed by immunohistochemical staining. The mRNA expressions of c-myc, extracellular signal-regulated kinase 2 (ERK2), MAPK phosphatase-1 (MKP-1) and endothelial nitric oxide synthase (eNOS) were determined by real-time reverse transcription-polymerase chain reaction. The protein expressions of MKP-1 and phosphorylated ERK2 (p-ERK2) were examined by Western blotting. The plasma contents of nitric oxide (NO) and cyclic guanosine 3',5'-monophosphate (cGMP) were also determined.
RESULTSCompared with the model group, Rut treatment significantly decreased intimal thickening and ameliorated endothelial injury (P<0.05 or P<0.01). The positive expression rate of PCNA was decreased, while the expression rate of SM α-actin obviously increased in the vascular wall after Rut (50 and 75 mg/kg) administration (P<0.05 or P<0.01). Furthermore, the mRNA expressions of c-myc, ERK2 and PCNA were downregulated while the expressions of eNOS and MKP-1 were upregulated (P<0.05 or P<0.01). The protein expressions of MKP-1 and the phosphorylation of ERK2 were upregulated and downregulated after Rut (50 and 75 mg/kg) administration (P<0.05 or P<0.01), respectively. In addition, Rut dramatically reversed balloon injury-induced decrease of NO and cGMP in the plasma (P<0.05 or P<0.01).
CONCLUSIONRut could inhibit the balloon injury-induced carotid intimal hyperplasia in rats, possibly mediated by promotion of NO production and inhibiting ERK2 signal transduction pathways.
Actins ; metabolism ; Animals ; Carotid Arteries ; drug effects ; metabolism ; pathology ; Carotid Artery Injuries ; drug therapy ; genetics ; pathology ; Cyclic GMP ; blood ; Disease Models, Animal ; Gene Expression Regulation ; drug effects ; Hyperplasia ; Indole Alkaloids ; pharmacology ; therapeutic use ; Male ; Nitric Oxide ; blood ; Phosphorylation ; drug effects ; Proliferating Cell Nuclear Antigen ; metabolism ; Quinazolines ; pharmacology ; therapeutic use ; RNA, Messenger ; genetics ; metabolism ; Rats, Sprague-Dawley ; Tunica Intima ; drug effects ; pathology
5.Inhibition of Janus activated kinase-3 protects against myocardial ischemia and reperfusion injury in mice.
Young Bin OH ; Min AHN ; Sang Myeong LEE ; Hyoung Won KOH ; Sun Hwa LEE ; Suhn Hee KIM ; Byung Hyun PARK
Experimental & Molecular Medicine 2013;45(5):e23-
Recent studies have documented that Janus-activated kinase (JAK)-signal transducer and activator of transcription (STAT) pathway can modulate the apoptotic program in a myocardial ischemia/reperfusion (I/R) model. To date, however, limited studies have examined the role of JAK3 on myocardial I/R injury. Here, we investigated the potential effects of pharmacological JAK3 inhibition with JANEX-1 in a myocardial I/R model. Mice were subjected to 45 min of ischemia followed by varying periods of reperfusion. JANEX-1 was injected 1 h before ischemia by intraperitoneal injection. Treatment with JANEX-1 significantly decreased plasma creatine kinase and lactate dehydrogenase activities, reduced infarct size, reversed I/R-induced functional deterioration of the myocardium and reduced myocardial apoptosis. Histological analysis revealed an increase in neutrophil and macrophage infiltration within the infarcted area, which was markedly reduced by JANEX-1 treatment. In parallel, in in vitro studies where neutrophils and macrophages were treated with JANEX-1 or isolated from JAK3 knockout mice, there was an impairment in the migration potential toward interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1), respectively. Of note, however, JANEX-1 did not affect the expression of IL-8 and MCP-1 in the myocardium. The pharmacological inhibition of JAK3 might represent an effective approach to reduce inflammation-mediated apoptotic damage initiated by myocardial I/R injury.
Animals
;
Apoptosis/drug effects
;
Cell Movement/drug effects
;
Chemokines/pharmacology
;
Heart Function Tests/drug effects
;
Inflammation/pathology
;
Janus Kinase 3/*antagonists & inhibitors/metabolism
;
Macrophages/drug effects/metabolism/pathology
;
Male
;
Mice
;
Mice, Inbred C57BL
;
Myocardial Reperfusion Injury/drug therapy/*enzymology/physiopathology/*prevention & control
;
Myocardium/enzymology/pathology
;
Myocytes, Cardiac/drug effects/metabolism/pathology
;
Neutrophils/drug effects/metabolism/pathology
;
Quinazolines/pharmacology/therapeutic use
6.EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Hyun CHANG ; Ji Hea SUNG ; Sung Ung MOON ; Han Soo KIM ; Jin Won KIM ; Jong Seok LEE
Yonsei Medical Journal 2017;58(1):9-18
PURPOSE: Rearrangement of the proto-oncogene rearranged during transfection (RET) has been newly identified potential driver mutation in lung adenocarcinoma. Clinically available tyrosine kinase inhibitors (TKIs) target RET kinase activity, which suggests that patients with RET fusion genes may be treatable with a kinase inhibitor. Nevertheless, the mechanisms of resistance to these agents remain largely unknown. Thus, the present study aimed to determine whether epidermal growth factor (EGF) and hepatocyte growth factor (HGF) trigger RET inhibitor resistance in LC-2/ad cells with CCDC6-RET fusion genes. MATERIALS AND METHODS: The effects of EGF and HGF on the susceptibility of a CCDC6-RET lung cancer cell line to RET inhibitors (sunitinib, E7080, vandetanib, and sorafenib) were examined. RESULTS: CCDC6-RET lung cancer cells were highly sensitive to RET inhibitors. EGF activated epidermal growth factor receptor (EGFR) and triggered resistance to sunitinib, E7080, vandetanib, and sorafenib by transducing bypass survival signaling through ERK and AKT. Reversible EGFR-TKI (gefitinib) resensitized cancer cells to RET inhibitors, even in the presence of EGF. Endothelial cells, which are known to produce EGF, decreased the sensitivity of CCDC6-RET lung cancer cells to RET inhibitors, an effect that was inhibited by EGFR small interfering RNA (siRNA), anti-EGFR antibody (cetuximab), and EGFR-TKI (Iressa). HGF had relatively little effect on the sensitivity to RET inhibitors. CONCLUSION: EGF could trigger resistance to RET inhibition in CCDC6-RET lung cancer cells, and endothelial cells may confer resistance to RET inhibitors by EGF. E7080 and other RET inhibitors may provide therapeutic benefits in the treatment of RET-positive lung cancer patients.
Adenocarcinoma/drug therapy/*genetics
;
Cell Line, Tumor
;
Cetuximab/pharmacology
;
Drug Resistance, Neoplasm/drug effects/*genetics
;
Epidermal Growth Factor/metabolism/*pharmacology
;
*Gene Rearrangement
;
Hepatocyte Growth Factor/*pharmacology
;
Humans
;
Indoles/pharmacology
;
Lung Neoplasms/drug therapy/*genetics
;
MAP Kinase Signaling System
;
*Mutation
;
Niacinamide/analogs & derivatives/pharmacology
;
Phenylurea Compounds/pharmacology
;
Piperidines/pharmacology
;
Protein Kinase Inhibitors/therapeutic use
;
Proto-Oncogene Proteins c-ret/*antagonists & inhibitors/genetics
;
Pyrroles/pharmacology
;
Quinazolines/pharmacology
;
RNA, Small Interfering/pharmacology
;
Receptor, Epidermal Growth Factor/genetics/metabolism
;
Signal Transduction/drug effects
;
fms-Like Tyrosine Kinase 3/metabolism